Another Targeted Advance in Treating NSCLC

-

The U.S. Food and Drug Administration (FDA) recently approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations.    This new approval extends only to patients whose tumors express specific mutations, originally identified by National Foundation for Cancer Research (NFCR)-supported scientist Daniel Haber, M.D., Ph.D. at Massachusetts General Hospital (MGH), which make them especially responsive to the drug. With this approval, metastatic non-small cell lung cancer patients whose tumors have EGFR mutations now have three personalized treatment options. 

It was Dr. Haber’s landmark research in 2004 that first identified the specific EGFR mutations that predict which patients will have a positive response to Iressa. In making its ruling, the FDA cites a recent clinical trial, which directly credits Dr. Haber’s research as instrumental in its success. One of the landmark achievements of the era of precision medicine was the effort to solve the puzzle of the drug Iressa. Why did only 13% of patients respond well to the drug? How could we screen for this small group of patients? These critical questions needed to be answered to unlock the true power of this drug – matching it with the patients who would most benefit. 

This breakthrough discovery not only helps to tailor Iressa to the right cancer patients, it also has profound indication in guiding the usage of other drugs, such as Tarceva, which also works by blocking EGFR. It is an illustration of targeted therapy in the new age of precision medicine. Research being done by scientists such as Dr. Haber and his team has expanded the work on identifying genetic lesions across multiple cancer types. Another example of how we are all in this together.

 

Popular posts from this blog

The Power of Community: The White Ribbon Project

-
Image
The Greek meaning of evangelist is "bringing the good news." It's why I call my podcast the Research Evangelist Podcast. I love to share stories about people in life sciences who are doing amazing work to advance cancer research. And it's why The White Ribbon Project has captured my attention. The White Ribbon Project is a grassroots movement of lung cancer patients, advocates, clinicians, researchers friends and families with a mission to change the public perception of lung cancer by spreading awareness that anyone with lungs can get lung cancer. No one deserves lung cancer whether you smoked or not. But lung cancer is not just a smokers disease, as more and more people are getting lung cancer with no smoking history. The White Ribbon Project is proving that the power of a community that cares can be unleashed by individuals who wanted to make a difference - people that didn't set out to start a movement. It's because their story is so sincere and authentic
Read more

Online Cancer Communities and Serendipity

-
Image
I've often told friends that I believe in serendipity. One definition of serendipity is "the occurrence and development of events by chance in a happy or beneficial way." Or even better maybe, "an aptitude for making desirable discoveries by accident." It's like saying "it's a small world." That happens to me a lot, but the world is not small unless you make the effort to actively connect with people and engage in real human conversations. And if you use the online tools available in the way they were meant to work, like Twitter, you can make real human connections by sharing what you care about with the world. Online communities provide opportunities to build authentic connections that can blossom into offline friendships, business relationships and networking. In the online cancer communities, really positive and interesting things happen to me often. I recently made an amazing new connection that came about because of some old connections an
Read more

Meet Ellen Skala: Super Advocate

-
Image
I was in Washington, D.C. recently on Capitol Hill meeting with my representatives in Congress to advocate for federal funding for biomedical research. As I’ve written many times, I believe government agencies like National Institutes of Health (NIH) , National Cancer Institute (NCI) and Department of Defense (DoD) play a critical role in advancing science and making discoveries that impact millions of lives. As a lung cancer survivor, I’ve advocated for cancer research for many years. This time I was on the hill on behalf of the organization I work for,  FRAXA Research Foundation , advocating for Fragile X research on Advocacy Day, an event organized by the National Fragile X Foundation. And I met an advocate that inspired me and reinforced my long-held belief that one person can make a difference. Meet Ellen Skala. Ellen Skala, also referred to as Elle, was on Capitol Hill to advocate that day too. I had spoken with her several times, but I had never met her in person.
Read more